<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:media="http://search.yahoo.com/mrss/"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>we39re &#8211; USA NEWS LIVE</title>
	<atom:link href="https://bloggingthree.soflytech.com/tag/we39re/feed/" rel="self" type="application/rss+xml" />
	<link>https://bloggingthree.soflytech.com</link>
	<description>All About USA NEWS</description>
	<lastBuildDate>Thu, 26 Dec 2024 00:38:58 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://bloggingthree.soflytech.com/wp-content/uploads/2024/04/cropped-THE-USA1-e1713184454543-1-32x32.png</url>
	<title>we39re &#8211; USA NEWS LIVE</title>
	<link>https://bloggingthree.soflytech.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>The stock in our latest portfolio has come back from its recent 52-week high &#8211; so we&#039;re buying more</title>
		<link>https://bloggingthree.soflytech.com/2024/12/the-stock-in-our-latest-portfolio-has-come-back-from-its-recent-52-week-high-so-were-buying-more/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Thu, 26 Dec 2024 00:38:57 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[52week]]></category>
		<category><![CDATA[buying]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[latest]]></category>
		<category><![CDATA[portfolio]]></category>
		<category><![CDATA[stock]]></category>
		<category><![CDATA[we39re]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=21587</guid>

					<description><![CDATA[We buy 300 shares of Bristol-Myers Squibb for about $58 each. After trading on Wednesday, Jim Cramer&#39;s Charitable Trust will own 900 BMY shares, increasing its weighting to about 1.5% from 1%. Shares of drugmaker Bristol-Myers have fallen about 3% prior to now two days amid a scarcity of real news. The stock hit a [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div>
<div data-test="articleBody-2" data-analytics="RegularArticle-articleBody-5-2">
<p><span hidden="" aria-hidden="true" class="ArticleBody-extraData"><span hidden="" aria-hidden="true" class="ArticleBody-extraData"><span hidden="" aria-hidden="true" class="xyz-data">We buy 300 shares of Bristol-Myers Squibb for about $58 each. After trading on Wednesday, Jim Cramer&#39;s Charitable Trust will own 900 BMY shares, increasing its weighting to about 1.5% from 1%. Shares of drugmaker Bristol-Myers have fallen about 3% prior to now two days amid a scarcity of real news. The stock hit a 52-week high on Monday. We are using the decline to maneuver deeper into this recently initiated position. We removed Bristol-Myers from our bullpen watch list on November twenty fifth. Here you&#8217;ll find out what&#39;s happening in the corporate and why we own it. Bristol-Myers is within the midst of a transition under the leadership of CEO Chris Boerner. It tackles considered one of the pharmaceutical industry&#39;s biggest patent cliffs, as key products comparable to blood clot prevention drug Eliquis and lung cancer treatment Opdivo lose patent protection and face generic competition in the following few years. The lack of patent protection will cause the corporate&#39;s overall revenue to say no by 2029. The market already understands this dynamic well. That&#39;s why Bristol-Myers shares currently trade at about eight times the consensus estimate for 2025 earnings per share. What the market is currently underestimating is Cobenfy&#39;s sales potential. This drug was acquired last December when Bristol-Myers bought Karuna Therapeutics for $14 billion. This deal was considered one of many multi-billion dollar acquisitions Bristol Myers made to replenish its pipeline. BMY 5Y Mountain Bristol-Myers Squibb 5 years In September, the FDA approved Cobenfy for the treatment of schizophrenia in adults. It is the primary novel drug against the disease in over 30 years. According to JPMorgan analysts, schizophrenia is a market price greater than $20 billion within the United States. We expect Bristol-Myers to dominate on this space after AbbVie&#39;s rival drug recently failed in two mid-stage trials. AbbVie&#39;s failure gives Cobenfy a transparent path to victory on this space. JPMorgan currently estimates annual Cobenfy sales at $5 billion by 2030. But analysts said they wouldn&#39;t be surprised to see peak sales within the $10 billion-plus range if the drug were approved for added indications. The addition of such a potentially large product is a giant deal considering Bristol-Myers is predicted to generate about $47 billion in sales this 12 months. Bristol-Myers&#39; price-to-earnings ratio should rise again as Cobenfy&#39;s sales rise in the approaching years &#8211; which might ease investors&#39; concerns in regards to the company&#39;s growth after the patent cliff. Finally, we like that Bristol-Myers is paying a giant dividend while we wait. The stock currently has an annual dividend yield of roughly 4.15%. (Jim Cramer&#39;s Charitable Trust is long BMY bond. See a full list of stocks here.) As a subscriber to CNBC Investing Club with Jim Cramer, you&#8217;ll receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable foundation&#39;s portfolio. If Jim discussed a stock on CNBC television, he waits 72 hours after the trade alert is issued before executing the trade. THE INVESTING CLUB INFORMATION SET FORTH ABOVE IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY, ALONG WITH OUR DISCLAIMER. THERE ARE NO fiduciary duty or duty IN RECEIVING YOUR INFORMATION PROVIDED IN CONNECTION WITH THE INVESTMENT CLUB. NO SPECIFIC RESULTS OR PROFITS ARE GUARANTEED.</span></span></span><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/108039887-1727381992515-karxt_product_image_bottles_720.jpg?v=1727382054&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
		<item>
		<title>We&#039;re increasing our position in a stock that just received major support on Wall Street</title>
		<link>https://bloggingthree.soflytech.com/2024/12/were-increasing-our-position-in-a-stock-that-just-received-major-support-on-wall-street/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Tue, 17 Dec 2024 00:09:08 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Increasing]]></category>
		<category><![CDATA[major]]></category>
		<category><![CDATA[Position]]></category>
		<category><![CDATA[received]]></category>
		<category><![CDATA[stock]]></category>
		<category><![CDATA[street]]></category>
		<category><![CDATA[support]]></category>
		<category><![CDATA[wall]]></category>
		<category><![CDATA[we39re]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=21039</guid>

					<description><![CDATA[Shortly after the bell opens, we are going to purchase 300 shares of Bristol Myers Squibb for about $56.50. After trading, Jim Cramer&#39;s Charitable Trust will own 1,200 shares of BMY, increasing its weighting within the portfolio from about 1.4% to about 1.9%. Wall Street&#39;s poor breadth can have finally caught up with them. The [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div>
<div data-test="articleBody-2" data-analytics="RegularArticle-articleBody-5-2">
<p><span hidden="" aria-hidden="true" class="ArticleBody-extraData"><span hidden="" aria-hidden="true" class="ArticleBody-extraData"><span hidden="" aria-hidden="true" class="xyz-data">Shortly after the bell opens, we are going to purchase 300 shares of Bristol Myers Squibb for about $56.50. After trading, Jim Cramer&#39;s Charitable Trust will own 1,200 shares of BMY, increasing its weighting within the portfolio from about 1.4% to about 1.9%. Wall Street&#39;s poor breadth can have finally caught up with them. The S&#038;P Short Range Oscillator, our trusted momentum indicator, was oversold after Friday&#39;s mixed session, falling to minus 4.1%. According to our discipline, when the oscillator is oversold, it&#8217;s time to be opportunistic and buy stocks in quality corporations. In Thursday&#39;s Hometretch, we identified that Bristol Myers Squibb&#39;s recent plunge into the mid-$50s gave the impression of a chance, especially for the reason that stock lost about half of its gains from the failed attempt against AbbVies Rival schizophrenia had again distributed medication. Analysts at Jefferies now share our bullish long-term view on Bristol Myers. Analysts on Monday upgraded their rating to &#8220;Buy&#8221; from &#8220;Hold&#8221; and raised their price goal to $70 from $63. Jefferies cited three foremost reasons for its decision, which suggest an upside of 25% over the present share price. Analysts consider the drugmaker&#39;s top schizophrenia drug, Cobenfy, is heading in the right direction to turn into a serious blockbuster. They currently expect the drug to realize peak sales of $11 billion, well above the present Wall Street consensus of $6 billion. Jefferies can also be increasingly bullish on Bristol Myers&#39; pipeline. One drug the analysts highlighted was Milvexian, a blood-thinning drug currently in three advanced trials for the treatment of atrial fibrillation, acute coronary syndrome and secondary stroke prevention. Jefferies&#39; third bullish point was improved profit and loss visibility and Bristol Myers&#39; ability to handle the approaching patent crisis, particularly as a consequence of higher Cobenfy sales. We agree with all three reasons and consider the stock is just too low-cost to trade at lower than 8 times estimated 2025 EPS with a dividend yield of 4.4%. We first purchased Bristol Myers in late November and last added to our position on December 4th. (Jim Cramer&#39;s Charitable Trust is long BMY. See a full list of stocks here.) As a subscriber to CNBC Investing Club with Jim Cramer, you&#8217;ll receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable foundation&#39;s portfolio. If Jim discussed a stock on CNBC television, he waits 72 hours after the trade alert is issued before executing the trade. THE INVESTING CLUB INFORMATION SET FORTH ABOVE IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY, ALONG WITH OUR DISCLAIMER. THERE ARE NO fiduciary duty or duty IN RECEIVING YOUR INFORMATION PROVIDED IN CONNECTION WITH THE INVESTMENT CLUB. NO SPECIFIC RESULTS OR PROFITS ARE GUARANTEED.</span></span></span><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/108001404-1720016102726-gettyimages-1095609806-RinaldiAlexandria05.jpeg?v=1734356832&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
		<item>
		<title>Opinion columnists &#124;  Tufekci: This might be our last probability to stop bird flu in humans, and we&#039;re blowing it</title>
		<link>https://bloggingthree.soflytech.com/2024/05/opinion-columnists-tufekci-this-might-be-our-last-probability-to-stop-bird-flu-in-humans-and-were-blowing-it/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Wed, 01 May 2024 15:21:48 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[bird]]></category>
		<category><![CDATA[blowing]]></category>
		<category><![CDATA[chance]]></category>
		<category><![CDATA[columnists]]></category>
		<category><![CDATA[flu]]></category>
		<category><![CDATA[humans]]></category>
		<category><![CDATA[Opinion]]></category>
		<category><![CDATA[stop]]></category>
		<category><![CDATA[Tufekci]]></category>
		<category><![CDATA[we39re]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=2201</guid>

					<description><![CDATA[The outbreak of H5N1 avian influenza in dairy cows within the United States, first reported on March 25, has now spread to at the least 33 herds in eight states. Genetic evidence of the virus was recently present in industrial milk. Federal authorities maintain the milk supply is secure, but this latest development raises troubling [&#8230;]]]></description>
										<content:encoded><![CDATA[<p><img decoding="async" src="https://www.mercurynews.com/wp-content/uploads/2024/04/Bird_Flu_Dairy_Cows_50143.jpg?w=1400px&amp;strip=all" /></p>
<div>
<p>The outbreak of H5N1 avian influenza in dairy cows within the United States, first reported on March 25, has now spread to at the least 33 herds in eight states.  Genetic evidence of the virus was recently present in industrial milk.  Federal authorities maintain the milk supply is secure, but this latest development raises troubling questions on how widespread the outbreak actually is.</p>
<p>So far there is just one confirmed human case.  Rick Bright, an authority on the H5N1 virus and a member of President Joe Biden&#39;s coronavirus advisory committee, told me that is the defining moment.  “There is a fine line between one and 10 people with H5N1,” he said.  “By the time we discover 10, it’s probably too late” to contain it.</p>
<p>So I told him what I had heard from Sid Miller, the Texas agriculture commissioner.  He said he strongly suspects the outbreak occurred at the least in February.  The commissioner speculated that as much as 40% of herds within the Texas panhandle could have been infected on the time.</p>
<p>Bright was silent after which asked a really sensible query: “Isn’t anyone monitoring this?”</p>
<p>The H5N1 outbreak, already a devastating crisis for cattle farmers and their herds, has the potential to change into an infinite tragedy for the remainder of us.  But after spending the last two weeks attempting to get answers from our nation&#39;s health officials, I&#39;m shocked at how little they appear to learn about what&#39;s actually happening and the way little of what they know is shared in a timely manner becomes.</p>
<h4 class="">How bird flu spreads</h4>
<p>How exactly does infection spread between herds?  The U.S. Department of Agriculture, the Food and Drug Administration and the Centers for Disease Control and Prevention all say they&#8217;re working to search out out.</p>
<p>According to many public health officials, the viral load is especially high in infected cow&#39;s milk, raising the chance that the disease could also be transmitted through milking machines or through aerosol spray when milking room floors are cleaned with high-pressure cleaners.  Another possible route is cow feed, because the U.S. allows farmers to feed leftover poultry bedding material — feathers, excrement, spilled seeds — to dairy and beef cattle as an affordable source of additional protein.</p>
<p>Worryingly, the USDA told me that it had evidence that the virus had also spread from dairy farms back to poultry farms “through an unknown route.”  Well, one thing that goes backwards and forwards between cattle ranches and chicken farms is people.  They may travel from cattle farms to pig farms, and pigs are the killer animals for human flu pandemics.</p>
<p>The USDA also told me that it doesn&#8217;t know the way many farmers have tested their cattle and doesn&#8217;t know the way lots of those tests have come back positive.  Whatever testing is finished takes place on the state level or in private laboratories.  Recently, the agency made reporting of all positive results mandatory, a protracted overdue step that – without the accompanying negative results – continues to be not enough to present us a whole picture.  Additionally, the USDA has mandated testing for dairy cattle moving from one state to a different.  It says mandatory testing of other flocks wouldn&#8217;t be &#8220;practical, feasible or necessarily informative&#8221; for &#8220;several reasons ranging from laboratory capacity to test turnaround times&#8221;.  At most, the authority will recommend voluntary testing for cattle that show symptoms of the disease &#8211; which will not be the case for all infected people.  Bright compares this to the Trump administration&#39;s approach to COVID-19: If you don&#39;t test, it doesn&#39;t exist.</p>
<p>The FDA tells me it has not conducted any specific tests to substantiate that pasteurization would make milk from infected cows secure, although the agency considers this &#8220;very likely&#8221; based on extensive testing for other pathogens.  (It will not be yet clear whether the weather of the H5N1 virus that recently appeared in milk have been completely neutralized.) These tests must be accomplished by now.  In any case, unpasteurized milk stays legal in lots of states.</p>
<p>Making matters worse, the USDA did not share the genomes of infected animals in a timely manner and did so in an unwieldy format and without geographic information, leaving scientists tearing their hair out in frustration.</p>
<h4 class="">Too few tested</h4>
<p>All of this makes it so urgent to discover potential human cases.  Bright says that given a situation like this and the incontrovertible fact that undocumented farmworkers may not have access to health care, the federal government should use all sophisticated surveillance techniques, including wastewater testing, and publicly release the outcomes.  That doesn&#8217;t occur.  The CDC says it&#8217;s monitoring emergency room data for signs of an outbreak.  By the time enough individuals are sick enough to be noticed within the emergency room, it&#39;s almost definitely too late to stop it.</p>
<p>Local individuals are doing their best.  Adeline Hambley, a health official in Ottawa, Michigan, told me a few farm whose herd had tested positive.  The farm owner voluntarily provided the cellphone numbers to the employees and the employees received text messages asking them to report any potential symptoms.  Lynn Sutfin, an information officer on the Michigan Department of Health and Human Services, told me that the response rate to those texts and other types of outreach could be as high as 90%.  That&#39;s encouraging, however it&#39;s an excessive amount of to expect that a poor farmworker &#8211; out of fear of stigma, legal problems and economic loss &#8211; will all the time report even mild symptoms and stay home from work as instructed.</p>
<p>It&#39;s entirely possible that we&#39;ll get lucky with H5N1 and never manage to spread amongst humans.  Transmission from animals to humans is common, but pandemics are rare because they require a sequence of unlucky events to occur one after the opposite.  But pandemics are a numbers game, and a large-scale animal outbreak like this increases the risks.  When dangerous novel pathogens emerge in humans, there is just a small window of opportunity to stop them before they get uncontrolled.  Neither our animal husbandry practices nor our public health tools seem as much as the duty.</p>
</p>
</div>
<p><em>image credit : www.mercurynews.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://www.mercurynews.com/wp-content/uploads/2024/04/Bird_Flu_Dairy_Cows_50143.jpg?w=1024&#038;h=671" medium="image"></media:content>
	</item>
	</channel>
</rss>
